Creative Medical Technology Holdings received a Notice of Allowance for its ImmCelz™ patent.

1 report, 1 independent Updated Jul 11

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Keep exploring

Part of

Creative Medical Technology Holdings developed a cell-based immunotherapy for Type 1 Diabetes. All 1 developments

Coverage

Newest first; wire copies grouped

Jul 11GlobeNewswireCreative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling PHOENIX, July 11, 2025 (GLOBE NEWSWIRE) -- Cr